Abiopharma

🔍 Martell Bridget A (Executive)

Company: Aligos Therapeutics, Inc. (ALGS)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 5,860 shares of Stock Option (Right to Buy) at $5.5 per share (Derivative)
  Date: 2026-06-25 | Code: A | Expires: 2036-06-25 | equity_swap_involved: 0 | shares_owned_after: 5,860.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.